

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 409 607 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
30.10.1996 Bulletin 1996/44

(51) Int. Cl.⁶: **A61K 39/395**, C12P 21/08,
G01N 33/68, C07K 7/08,
G01N 33/68

(21) Application number: 90307879.8

(22) Date of filing: 19.07.1990

(54) **Antibody to human interleukin-6 receptor**

Antikörper gegen menschlichen Interleukin-6-Rezeptor

Anticorps contre le récepteur de l'interleukin-6

(84) Designated Contracting States:
AT BE CH DE ES FR GB IT LI NL SE

(30) Priority: 20.07.1989 JP 186016/89

(43) Date of publication of application:
23.01.1991 Bulletin 1991/04

(73) Proprietor: Kishimoto, Tadamitsu
Tondabayashi-shi Osaka (JP)

(72) Inventor: Kishimoto, Tadamitsu
Tondabayashi-shi Osaka (JP)

(74) Representative: Kearney, Kevin David Nicholas et
al
KILBURN & STRODE
30 John Street
London, WC1N 2DD (GB)

(56) References cited:

EP-A- 0 312 996 EP-A- 0 325 474

- BIOLOGICAL ABSTRACT NB 89015076 HIRATA Y. et al: "Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies
- CHEMICAL ABSTRACTS, vol. 110, no. 23, 5 June 1989, Columbus, Ohio, (US); K. YAMASAKI et al; p. 555, col. 1, ref.no. 210580E
- CHEMICAL ABSTRACTS, vol. 111, no. 1, 3 July 1989 Columbus, Ohio, USA YAMASAKI K. et al: p. 5582, col. 2, ref.no. 5589U

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 409 607 B1

Description

BACKGROUND OF THE INVENTION

(1) Field of the Invention

The present invention relates to antibodies which specifically bind to a human IL-6 receptor, and a process for the preparation thereof.

(2) Description of the Related Art

Interleukin-6 (hereinafter abbreviated to "IL-6") is a protein having various important physiological activities and participating broadly in the proliferation and differentiation of cells.

Furthermore, it is reported that an abnormal production of IL-6 is possibly a factor causing various autoimmune diseases (see Kishimoto and Hirano, *Ann. Rev. Immunol.*, 6, page 485, 1988).

IL-6 receptors on the cell membrane, which specifically bind to IL-6, were analysed by Taga et al., and the number on each cell and binding constant to IL-6 were reported (see *J. Exp. Med.*, 196, page 967, 1987). Furthermore, the cDNA of human IL-6 receptor was isolated, and the primary structure thereof was reported by Yamazaki et al. (see *Science*, 241, page 825, 1988). IL-6 receptor which is prepared by a genetic engineering method based on these results, is expected to become a therapeutic or diagnostic agent for various immune diseases.

Chemical Abstracts, Vol 110, No. 23, 5 June 1989, Columbus, Ohio, USA, Yamasaki K. et al "cloning and expression of human interleukin-6 (BSF-2/IFN-Beta 2) receptor" page 555, vol 1, ref no. 210580e indicates that human interleukin-6 receptor is another name for human B cell stimulating factor 2 receptor as used in EP-A-0325474.

This document, EP-A-0 325 474, cited under Article 54(3) EPC, discloses a monoclonal antibody (MT18) to human B cell stimulating factor 2 receptor. However this Mab is not competitive with human IL-6 for the binding to human IL-6 receptor.

For a mass production and homogeneous purification of such IL-6 receptors, the development of an antibody to the IL-6 receptor as a means for promptly identifying the IL-6 receptor is required, but a monoclonal antibody capable of recognizing the IL-6 receptor has not been known from the prior art according to Art 54(2) EPC.

SUMMARY OF THE INVENTION

The present invention provides a monoclonal antibody to human interleukin-6 receptor, which is capable of binding specifically to a human interleukin-6 receptor, and which is competitive with human interleukin-6 for the binding to a human interleukin-6 receptor, in particular PM1 antibody (FERM BP-2998).

Furthermore, the present invention provides hybridoma producing a monoclonal antibody having the above-mentioned properties.

The present invention further provides a process for the preparation of an antibody to a human interleukin-6 receptor, which comprises culturing the above-mentioned hybridoma and recovering a monoclonal antibody capable of recognizing a human interleukin-6 receptor from the culture.

The present invention further provides a peptide having a sequence represented by KTSMHPPYSLGQLVPC (ID No. 1) in which the alphabetic letters mean amino acids according to the one letter method. This peptide sequence could be used as an immunogen by the preparation of a polyclonal or monoclonal antibody to human interleukin-6 receptor.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the reactivity of a T-cell line Jurkat in which the IL-6 receptor is not expressed [curves (a) and (c)], or a Jurkat in which an IL-6 receptor cDNA-containing vector is introduced and the IL-6 receptor is durably expressed [curves (b) and (d)], with the culture supernatant of MT18 [solid lines in curves (a) and (b)] or the culture supernatant of PM1 [solid lines in curves (c) and (d)]. The dotted lines show the results for the cells not treated with the culture supernatant;

Fig. 2 shows the results obtained by solubilizing internally labelled U266 cells, effecting immunoprecipitation with an MT18 monoclonal antibody (lane 1), PM1 monoclonal antibody (lane 2), rabbit immunoglobulin (lane 3) or anti-peptide polyclonal antibody of Example 3 (lane 4), and subjecting same to SDS-polyacrylamide gel electrophoresis and auto-radiography;

Fig. 3 is a graph showing the inhibiting effects of PM1 and MT18 antibodies on the binding of IL-6 to the IL-6 receptor according to the procedure described in Example 4;

Fig. 4 shows the results of a comparison of the bindings of the MT18 antibody [curve (a)] and PM1 antibody [curve (b)] to U266 cells in the presence (broken line) or absence (solid line) of IL-6, and the dotted lines show the results for U266 cells treated with only IL-6;

Fig. 5 shows the incorporation of tritium-labelled thymidine by KT3 cells cultured with various concentrations of IL-6, in the presence or absence of the culture supernatant of MT18 or PM1; and

Fig. 6 is a cell distribution diagram showing that the MT18 antibody binds only IL-6 receptor-producing cells.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Monoclonal antibodies of the present invention specifically recognize a human IL-6 receptor. The monoclonal antibodies are competitively inhibiting the binding of human IL-6 to a human IL-6 receptor. Such antibodies, include, for example, PM1 monoclonal antibody produced by the hybridoma PM1 of the present invention.

As an immunogen used for the preparation of the antibodies of the present invention, there can be mentioned animal cells having human IL-6 receptors expressed on the surface thereof. Such animal cells include a human-derived cell line producing human IL-6 receptor, for example, human myeloma cell line U266, and host cells transformed with DNA coding for human IL-6 receptor, for example, animal cell line such as mouse T-cells transformed with a plasmid comprising cDNA coding for human IL-6 receptor. Nevertheless, these cell lines are not regarded as an effective antigen, because the quantity of the IL-6 receptor expressed on the cell surface is small.

Nevertheless, even though such an immunogen is used to produce an antibody, once an antibody to a human IL-6 receptor has been obtained, it is possible to prepare a more effective immunogen by using this antibody, and to prepare a variety of antibodies by using this immunogen. For example, an immunogen can be prepared by bonding an antibody to a human IL-6 receptor to an appropriate solid carrier, culturing cells producing a human IL-6 receptor, for example, the above-mentioned cells and lysing the cells, and bringing the cell lysate into contact with the above-mentioned human IL-6 receptor antibody-bonded solid carrier to adsorb and concentrate the human IL-6 receptor in the cell lysate on the carrier. The kind of solid carrier is not particularly critical, as long as the solid carrier is capable of binding the antibody and preferably has no serious influence on the growth of an animal to be immunized. For example, a Sepharose-based solid carrier, as described in the Examples hereinafter, is preferably used as the solid carrier in the present invention, because the binding of the antibody to this carrier is a simple operation and there are no influences on the growth of an animal to be immunized. Alternatively, human IL-6 receptor can be prepared according to a genetic engineering process, for example, the process disclosed in JP-A-02288898 (Japanese Patent Application 89-977), and this receptor can be used as the immunogen. Still further, an immunogen prepared by forming a peptide comprising a part of a human IL-6 receptor and attaching this peptide to a polymeric carrier for example a protein such as ovalbumin can be used. A vaccinia virus arranged so that human IL-6 receptor will be expressed after the infection also can be used as an immunogen. Any of these immunogens can be used as the immunogen for the preparation of a polyclonal antibody and for the preparation of a hybridoma.

Polyclonal antibody is prepared by immunizing a mammal such as mouse, rabbit, sheep, goat or the like with a peptide (ID No.1) of the present invention, according to conventional procedures.

Hybridoma can be prepared according to conventional procedures, for example, by immunizing a mammal such as a mouse with any of the above-mentioned antigens, obtaining spleen cells from this animal, fusing the cells with established myeloma cells, and then cloning a hybridoma producing a monoclonal antibody having a desired reactivity.

A monoclonal antibody is prepared by culturing the cloned hybridoma and recovering the monoclonal antibody from the culture supernatant. Alternatively, a monoclonal antibody can be prepared by intraperitoneally infecting an animal with the above-mentioned hybridoma, collecting ascites from the animal, and isolating the monoclonal antibody. The antibody in the hybridoma cell supernatant or the antibody in the ascites can be concentrated according to a conventional procedure, for example, by salting-out with ammonium sulfate, and can be purified by an affinity chromatography, for example, an affinity chromatography on an IL-6 receptor-immobilized carrier.

All of the processes for the preparation of the monoclonal antibody, the preparation of the hybridoma, the preparation of the monoclonal antibody, and the recovery and purification of the antibody can be carried out according to methods well-known in the art.

The present invention will now be described in detail with reference to the following examples, that by no means limit the scope of the invention.

Comparative Example 1 (Preparation of mouse monoclonal antibody to human IL-6 receptor)

For preparing a mouse monoclonal antibody to human IL-6 receptor, a mouse T-cell line having human IL-6 receptors expressed on the membrane surface was prepared as an immunogen, according to the following process. Namely, pBSF2R.236 and pSV2neo disclosed in the JP-A-02288898 (Japanese Patent Application No. 89-9774) were introduced into mouse T-cells CTLL-2 (ATCC, TIB214) according to a conventional method, and the screening was carried

out according to a conventional method using G-418. Finally, a cell line in which about 30,000 IL-6 receptors per cell were expressed was established and named "CTBC3".

Immunization was carried out in the following manner. Namely, CTBC3 was cultured by a conventional method using PRM1640, washed with PBS buffer 4 times, and was intraperitoneally introduced to C57BL6 mouse in a quantity of 1×10^7 cells per mouse once a week, six times as a whole.

The spleen cells from the immunized mouse were fused with myeloma cells P3U1 as a parent cell line, according to a conventional method using polyethylene glycol.

The screening was carried out in the following manner. Namely, pBSF2R.236 and pSV2neo were introduced into human T-cells JURKAT (ATCC, CRL8163) negative to the IL-6 receptor, and after screening, a cell line in which about 100,000 IL-6 receptors per cell were expressed was established and named "NJBC8". One clone of hybridoma producing an antibody which recognizes NJBC8 solubilized with NP40 and does not recognize JURKAT solubilized with NP40, was isolated and this hybridoma was named "MT18". Furthermore, the monoclonal antibody produced by this hybridoma was named "MT18 antibody". The above-mentioned hybridoma MT18 was deposited at the Fermentation Research Institute (FRI) Agency of Industrial Science and Technology 1-3 Yatabe-cho Higashi 1-chome Ibaraki Japan as FERM P-10840 on July 12, 1989, and transferred to an international deposition under the Budapest Treaty as FERM BP-2999 on July 10, 1990. The data of Fig. 6 shows that the MT18 antibody specifically recognizes the IL-6 receptor. In Fig. 6, curve A shows the distribution of fluorescein-stained cells, when JURKAT cells are stained with the MT18 antibody labelled with fluorescein isocyanate, and curve B shows the result when the above-mentioned NJBC8 cell is similarly treated.

Example 2 (Preparation of monoclonal antibody to IL-6 receptor)

For preparing a mouse monoclonal antibody to IL-6 receptor, human IL-6 receptors were extracted as an immunogen in the following manner.

Namely, 3×10^9 human myeloma cells of cell line U266 (IL-6 receptor-producing cells) were solubilized with 1 ml of 1% digitonin (supplied by Wako Junyaku), 10 mM triethanolamine buffer (pH 7.4), 0.15 M NaCl and 1 mM PMSF (supplied by Wako Junyaku). On the other hand, MT18 antibody (Example 1), i.e., an antibody to IL-6 receptor, was attached to Sepharose 4B (supplied by Pharmacia) according to a conventional manner. The antibody-bonded carrier was mixed with a supernatant of the solubilized cells to bond the solubilized IL-6-receptor to the MT18 antibody on the carrier. Non-specifically bonded product was washed off with the above-mentioned 1% digitonin solution, and the IL-6 receptor bonded to the Sepharose 4B[®] through the MT18 antibody was used as an immunogen for one immunization.

The immunization and the preparation of hybridoma were carried out in the following manner. A Balb/c mouse was immunized intraperitoneally with the above-mentioned immunogen four times, once a week. The spleen cells from the mouse were fused with myeloma cells P3U1 as a parent cell line, according to a conventional process using polyethylene glycol.

The screening was carried out in the following manner. First, a culture supernatant of the hybridoma was mixed with Protein G-Sepharose[®] resin (supplied by Pharmacia), whereby immunoglobulin in the supernatant was adsorbed to the resin. On the other hand, 10^7 U266 cells internally labelled with ³⁵S-methionine were solubilized, and then, the IL-6-receptor was affinity-purified on the above-mentioned MT18 antibody-bonded Sepharose 4B described above, immunoprecipitated with the above-mentioned Protein G-Sepharose[®], and analyzed by SDS/PAGE. As a result, one clone of hybridoma producing an antibody which specifically binds to IL-6 receptor was isolated and named "PM1". The monoclonal antibody produced by this hybridoma was named "PM1 antibody".

The hybridoma PM1 was deposited at the Fermentation Research Institute (FRI) of Agency of Industrial Science and Technology in Japan as FERM-P 10839 on July 12, 1989, and transferred to an international deposition under the Budapest Treaty as FERM BP-2998 on July 10, 1990.

The reactivities of the monoclonal antibodies PM1 and MT18 with the IL-6 receptor are shown in Fig. 1. Namely, the T-cell line Jurkat in which the IL-6 receptor was not expressed [curves (a) and (c) in Fig. 1] and the cell line Jurkat in which cDNA of the IL-6 receptor has been introduced and the IL-6-receptor was durably expressed (curves (b) and (d)), were separately reacted with a culture supernatant of MT18 [solid lines in curves (a) and (b) in Fig. 1] or of PM1 [solid lines in curves (c) and (d)]. The reaction products were reacted with a goat anti-mouse antibody conjugated to a fluorescence dye, and the distribution of the fluorescein-stained cells relative to the fluorescein intensity was examined. For comparison, the results obtained from corresponding cells treated with neither the culture supernatant of MT18 or PM1, are indicated by dotted lines in boxes (a), (b), (c) and (d) in Fig. 1.

From these results, it was confirmed that each of the PM1 and MT18 antibodies can be bonded to the IL-6 receptor.

Example 3 (Preparation of polyclonal antibody to IL-6 receptor)

For preparing a polyclonal antibody to IL-6 receptor, a peptide: KTSMHPPYSLGQLVPC (ID No.1) (K represents lysine, T represents threonine, S represents serine, M represents methionine, H represents histidine, F represents phe-

nyltalanine, P represents proline, Y represents tyrosine, L represents leucine, G represents glycine, Q represents glutamine, V represents valine, and C represents cysteine residue) in which a cysteine residue is added to a peptide corresponding to a part of the intracellular region of an IL-6 receptor (ID. No.2) was synthesized according to a conventional method.

This synthetic peptide was attached to ovalbumin according to the process of T. Hirano et al (Proc. Natl. Acad. Sci. USA, 84, page 228, 1987). A rabbit was immunized with 0.2 mg of the product 5 times once a week. The whole serum was collected from the rabbit and subjected to affinity purification on a synthetic peptide-bound Sepharose® 4B.

The data shown in Fig. 2 indicates that the prepared polyclonal antibody can specifically recognize the IL-6 receptor. Namely, internally labelled U266 cells (IL-6 receptor-producing cells) were solubilized with a detergent, and the obtained cell lysate was immunoprecipitated with the MT18 antibody (lane 1), the PN1 antibody (lane 2), rabbit immunoglobulin (lane 3) or the anti-peptide polyclonal antibody prepared in Example 3 (lane 4) and then subjected to SDS-polyacrylamide gel electrophoresis and autoradiography. As a result, it was confirmed that each of the MT18 monoclonal antibody, the PM1 monoclonal antibody and the anti-peptide polyclonal antibody specifically recognized the IL-6 receptor.

Example 4 (Competitive inhibition of binding of IL-6 to IL-6 receptor by PM1 antibody)

Labelling of IL-6 and identification of binding of IL-6 to an IL-6 receptor on cell were carried out according to the method of T. Taga et al. (see J. Exp. Med., 166, page 967, 1987). ^{125}I -IL-6 (14,000 cpm) was reacted with 4×10^5 of U266 cells (IL-6 receptor-producing cells) at room temperature for 60 minutes. This reaction was carried out in the presence of unlabelled IL-6 in 100-fold excess of the number of molecules, the culture supernatant of MT18 (70% by volume) or the culture supernatant of PM1 (70% by volume). The cells were overlaid on FCS, centrifuged, and the radioactivity of the cells was measured. For comparison, a culture medium not inoculated with the cells was similarly treated.

The data of Fig. 3 indicates that the MT18 antibody does not competitively inhibit the binding of IL-6 to the IL-6 receptor while the PM1 antibody competitively inhibits this binding.

Similar results are also shown in Fig. 4. In Fig. 4, curve (a) shows the distribution of the number of cells relative to the fluorescence intensity, in which U266 cells were reacted with the culture supernatant of MT18 in the presence (broken line) or absence (solid line) of IL-6 and then stained with fluorescence-labelled anti-mouse immunoglobulin; and curve (b) shows the results when U266 cells were reacted with the culture supernatant of PM1 in the presence (broken line) or absence (solid line) of IL-6 and treated in the same manner as curve (a). It is seen that the MT18 antibody was bonded to the U266 cells whether in the presence of IL-6 or not, while the PM1 antibody was bonded to the U266 cells in the absence of IL-6 but not bonded to the U266 cells in the presence of an excess of IL-6. Accordingly, it is confirmed that the PM1 antibody is competitive with IL-6.

Example 5 (Confirmation of inhibition of biological activities of IL-6 by PM1 antibody)

IL-6-dependent human T-cell leukemia line KT3 was cultured according to the process of S. Shimizu et al. (see Blood, 72, page 1826, 1988), and IL-6 was added at various concentrations in the presence or absence of 25% by volume of the culture supernatant of the hybridoma PM1. Culturing was conducted in a commercially available 96-well plate. The cell number was 5×10^3 per $100 \mu\text{l}$ in each well. After 60 hours, $0.75 \mu\text{Ci}$ of tritium-labelled thymidine per well was added, and after 6 hours, the cells were collected and the incorporated radioactivity was measured.

Data of Fig. 5 indicates that the MT18 antibody does not inhibit the biological activities of IL-6 while the PM1 antibody inhibits the biological activities of IL-6.

The polyclonal and monoclonal antibodies recognizing specifically IL-6 receptor, provided by the present invention, are useful for producing and purifying large quantities of various proteins having an IL-6 receptor activity which are expected as diagnostic or therapeutic agents.

Furthermore, the antibody provided by the present invention make it possible to analyze various properties of IL-6 receptor which is produced only in a very small amount in the natural state. This is very significant for an investigation of ontogenesis and immune mechanisms, and for a development of therapeutic and diagnostic agents based on the results thereof.

Moreover, it is considered that the antibody inhibiting biological activities of IL-6, provided by the present invention, will be applied to the development of therapeutic agents for various autoimmune diseases assumed to be caused by an abnormal production of IL-6.

Example 6 (Preparation of monoclonal antibody to a portion of IL-6 receptor)

Balb/c mouse was intraperitoneally immunized with the antigen used in Example 3, i.e., a synthetic peptide KTSMHPPYSLGQLVPC (ID No.1) conjugated with ovalbumin, four times once a week. Next, the spleen cells from the mouse were fused with myeloma cells using polyethylene glycol according to a conventional process.

The screening was carried out in the following manner. First, a culture supernatant of the hybridoma was mixed with Protein G-Sepharose® resin (Pharmacia), whereby immunoglobulin in the supernatant was adsorbed to the resin. On the other hand, 10⁷ U266 cells internally labelled with ³⁵S-methionine were solubilized, immunoprecipitated with the above-mentioned Protein G-Sepharose®, and analyzed by SDS/PAGE. As a result, a band of IL-6 receptor was detected. On the other hand, when the antigen peptide (KTSMHPPYSLGQLVPC) (ID No.1) was added during the immunoprecipitation, no band was detected. As a result, one clone of hybridoma which produces an monoclonal antibody specifically recognizing a portion of intracellular region of IL-6 receptor was isolated.

SEQ ID NO: 1

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 16 amino acids

**Lys-Thr-Ser-Met-His-Pro-Pro-Tyr-Ser-Leu-
Gly-Gln-Leu-Val-Pro-Cys**

SEQ ID NO: 2

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 15 amino acids

**Lys-Thr-Ser-Met-His-Pro-Pro-Tyr-Ser-Leu-
Gly-Gln-Leu-Val-Pro**

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, NL, SE

1. A monoclonal antibody to human interleukin-6 receptor, which is capable of binding specifically to a human interleukin-6 receptor, which is competitive with human interleukin-6 for the binding to a human interleukin-6 receptor.
2. An antibody as set forth in claim 1 which is PM1 antibody (FERM BP-2998).
3. A peptide having a sequence represented by KTSMHPPYSLGQLVPC (ID No. 1) in which the alphabetic letters mean amino acids according to the one letter method.
4. A hybridoma producing a monoclonal antibody as set forth in claim 1.
5. A process for the preparation of anti-human interleukin-6 receptor antibody, which comprises culturing a hybridoma as set forth in claim 4 and recovering a monoclonal antibody capable of recognizing a human interleukin-6 receptor from the culture.

Claims for the following Contracting State : ES

1. A process for the preparation of anti human interleukin-6 receptor antibody, which comprises culturing a hybridoma which produces a monoclonal antibody which is capable of binding specifically to a human interleukin-6 receptor, and which is competitive with interleukin-6 for the binding of human interleukin-6 receptor.
2. A process for the preparation of a peptide having the sequence:
KTSMHPPYSLGQLVPC (ID No. 1)
which comprises synthesising the peptide by conventional methods using the appropriate amino acids.
3. A process as claimed in claim 1 characterised in that the anti-human interleukin-6 receptor antibody is PM 1 antibody (FERM BP-2998).

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, NL, SE

1. Monoklonaler Antikörper gegen den Interleukin 6-Rezeptor, der zum spezifischen Binden am menschlichen Interleukin 6-Rezeptor befähigt ist und der mit menschlichem Interleukin 6 um die Bindung am menschlichen Interleukin 6-Rezeptor konkurriert.
2. Antikörper nach Anspruch 1, der ein PM1-Antikörper (FERM BP-2998) ist.
3. Peptid einer Sequenz, die durch KTSMHPPYSLGQLVPC (ID Nr. 1) wiedergegeben ist, wobei die alphabetischen Buchstaben Aminosäuren entsprechend dem Ein-Buchstaben-Code sind.
4. Hybridom, das einen monoklonalen Antikörper nach Anspruch 1 erzeugt.
5. Verfahren zur Herstellung eines gegen den menschlichen Interleukin 6-Rezeptor gerichteten Antikörpers, welches das Kultivieren eines Hybridoms nach Anspruch 4 und das Gewinnen eines monoklonalen Antikörpers aus der Kultur, der zum Erkennen des menschlichen Interleukin 6-Rezeptors befähigt ist, umfaßt.

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung eines gegen den menschlichen Interleukin 6-Rezeptor gerichteten Antikörpers, welches das Kultivieren eines Hybridoms, das einen monoklonalen Antikörper erzeugt, der zum spezifischen Binden an einem menschlichen Interleukin 6-Rezeptor befähigt ist und der mit Interleukin 6 um das Binden am menschlichen Interleukin 6-Rezeptor konkurriert, umfaßt.
2. Verfahren zur Herstellung eines Peptids der Sequenz KTSMHPPYSLGQLVPC (ID Nr. 1), welches die Synthese des Peptids durch herkömmliche Verfahrensweisen unter Verwendung der geeigneten Aminosäuren umfaßt.
3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß der gegen den menschlichen Interleukin 6-Rezeptor gerichtete Antikörper der PM 1-Antikörper (FERM BP-2998) ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, NL, SE

1. Anticorps monoclonal contre le récepteur de l'interleukine-6 humaine, qui est capable de se lier spécifiquement avec un récepteur de l'interleukine-6 humaine, et qui rivalise avec l'interleukine-6 humaine pour se lier avec un récepteur de l'interleukine-6 humaine.
2. Anticorps selon la revendication 1, qui est un anticorps PM1 (FERM BP-2998).
3. Peptide présentant une séquence représentée par KTSMHPPYSLGQLVPC (ID n°1) dans laquelle les lettres de l'alphabet se rapportent à des acides aminés selon le procédé une lettre/un acide aminé.
4. Hybridome produisant un anticorps monoclonal selon la revendication 1.

5. Procédé de préparation d'un anticorps du récepteur de l'interleukine-6 anti-humaine, qui comprend la mise en culture d'un hybridome selon la revendication 4 et la récupération d'un anticorps monoclonal capable de reconnaître un récepteur de l'interleukine-6 humaine dans une culture.

5 **Revendications pour l'Etat contractant suivant : ES**

1. Procédé de préparation d'un anticorps du récepteur de l'interleukine-6 anti-humaine, qui comprend la mise en culture d'un hybridome qui produit un anticorps monoclonal capable de se lier spécifiquement avec un récepteur de l'interleukine-6 humaine et qui rivalise avec l'interleukine-6 humaine pour se lier avec un récepteur de l'interleukine-6 humaine.
2. Procédé de préparation d'un peptide présentant la séquence :
KTSMHPPYSLGQLVPC (ID n°1)
qui comprend la synthèse du peptide par des méthodes classiques en utilisant les acides aminés appropriés
3. Procédé selon la revendication 1, caractérisé en ce que l'anticorps du récepteur de l'interleukine-6 anti-humaine est l'anticorps PM1 (FERM BP-2998).

Fig.1




Fig.2




Fig.3




Fig.4




Fig.5





Fig.6



REGISTER ENTRY FOR EP0409607

European Application No EP90307879.8 filing date 19.07.1990

Priority claimed:

20.07.1989 in Japan - doc: 01186016

Designated States BE CH DE ES FR GB IT LI NL SE AT

Title ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR.

Applicant/Proprietor

TADAMITSU KISHIMOTO, 5-31 Nakanochō 3-chōme, Tondabayashi-shi Osaka, Japan
[ADP No. 56709686001]

Inventor

TADAMITSU KISHIMOTO, 5-31 Nakanochō 3-chōme, Tondabayashi-shi Osaka, Japan
[ADP No. 56709686001]

Classified to

A61K C07K C12P G01N

Address for Service

KILBURN & STRODE, 30 John Street, LONDON, WC1N 2DD, United Kingdom
[ADP No. 00000125001]

EPO Representative

KEVIN DAVID NICHOLAS KEARNEY, KILBURN & STRODE 30 John Street, London,
WC1N 2DD, United Kingdom [ADP No. 50201169001]

Publication No EP0409607 dated 23.01.1991

Publication in English

Examination requested 29.11.1991

Patent Granted with effect from 30.10.1996 (Section 25(1)) with title ANTIBODY
TO HUMAN INTERLEUKIN-6 RECEPTOR

13.05.1991 EPO: Search report published on 12.06.1991

Entry Type 25.11 Staff ID. RD06 Auth ID. EPT

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

17/01/97 13:35:25
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER

EP0409607 /

PROPRIETOR(S)

Tadamitsu Kishimoto, 5-31 Nakanochō 3-chōme, Tondabayashi-shi Osaka,
Japan,

DATE FILED

19.07.1990 /

DATE GRANTED

30.10.1996 /

DATE NEXT RENEWAL DUE

19.07.1997

DATE NOT IN FORCE

DATE OF LAST RENEWAL

YEAR OF LAST RENEWAL

00

STATUS

PATENT IN FORCE

**** END OF REPORT ****